M. Mabry

发表

The genotype of the human cancer cell: implications for risk analysis.

J F Dicello, J R Williams, Jerry R. Williams, 1996, Mutation research.

A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

A. Letai, M. Konopleva, H. Kantarjian, 2014 .

Selective radiosensitization of p53–deficient cells by caffeine–mediated activation of p34cdc2 kinase

D. Sidransky, Richard J. Jones, M. Collector, 1996, Nature Medicine.

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.

A. Letai, M. Konopleva, H. Kantarjian, 2018, The Lancet. Oncology.

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

A. Wei, W. Fiedler, A. Enjeti, 2017 .

Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia

A. Letai, M. Konopleva, H. Kantarjian, 2017 .

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia

G. Martinelli, A. Wei, W. Fiedler, 2016 .

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

G. Giaccone, C. Rudin, M. Ranson, 2012, Clinical Cancer Research.

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

A. Letai, M. Konopleva, H. Kantarjian, 2016, Cancer discovery.

Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.

K. Götze, G. Garcia-Manero, Jacqueline S. Garcia, 2018 .

Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy.

A. Letai, M. Konopleva, H. Kantarjian, 2016 .

Cancer Therapy : Clinical Phase II Study of Single-Agent Navitoclax ( ABT-263 ) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

G. Giaccone, C. Rudin, G. Shapiro, 2012 .

A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors

V. Karantza, D. Cosgrove, G. Vlahović, 2014, Investigational New Drugs.

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

A. Letai, M. Konopleva, H. Kantarjian, 2015 .

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

G. Shapiro, H. Hurwitz, T. Busman, 2014, Investigational New Drugs.

A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)

F. Khuri, R. Herbst, J. Rigas, 2005 .

A randomized phase III trial comparing bexarotene/cisplatin/vinorelbine versus cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)

R. Ramlau, J. Jassem, P. Zatloukal, 2005 .

Abstract 2834: BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia

A. Keating, A. Letai, M. Konopleva, 2015 .

A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.

M. D. de Jonge, T. Busman, A. Krivoshik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.